108 related articles for article (PubMed ID: 29378070)
1. From the Cover: Inhibitors of Nicotinamide Phosphoribosyltransferase Cause Retinal Damage in Larval Zebrafish.
Cassar S; Dunn C; Olson A; Buck W; Fossey S; Ramos MF; Sancheti P; Stolarik D; Britton H; Cole T; Bratcher N; Huang X; Peterson R; Longenecker K; LeRoy B
Toxicol Sci; 2018 Feb; 161(2):300-309. PubMed ID: 29378070
[TBL] [Abstract][Full Text] [Related]
2. Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase.
Zabka TS; Singh J; Dhawan P; Liederer BM; Oeh J; Kauss MA; Xiao Y; Zak M; Lin T; McCray B; La N; Nguyen T; Beyer J; Farman C; Uppal H; Dragovich PS; O'Brien T; Sampath D; Misner DL
Toxicol Sci; 2015 Mar; 144(1):163-72. PubMed ID: 25505128
[TBL] [Abstract][Full Text] [Related]
3. Cardiotoxicity Associated with Nicotinamide Phosphoribosyltransferase Inhibitors in Rodents and in Rat and Human-Derived Cells Lines.
Misner DL; Kauss MA; Singh J; Uppal H; Bruening-Wright A; Liederer BM; Lin T; McCray B; La N; Nguyen T; Sampath D; Dragovich PS; O'Brien T; Zabka TS
Cardiovasc Toxicol; 2017 Jul; 17(3):307-318. PubMed ID: 27783203
[TBL] [Abstract][Full Text] [Related]
4. A fluorometric assay for high-throughput screening targeting nicotinamide phosphoribosyltransferase.
Zhang RY; Qin Y; Lv XQ; Wang P; Xu TY; Zhang L; Miao CY
Anal Biochem; 2011 May; 412(1):18-25. PubMed ID: 21211508
[TBL] [Abstract][Full Text] [Related]
5. Preclinical models of nicotinamide phosphoribosyltransferase inhibitor-mediated hematotoxicity and mitigation by co-treatment with nicotinic acid.
Tarrant JM; Dhawan P; Singh J; Zabka TS; Clarke E; DosSantos G; Dragovich PS; Sampath D; Lin T; McCray B; La N; Nguyen T; Kauss A; Dambach D; Misner DL; Diaz D; Uppal H
Toxicol Mech Methods; 2015 Mar; 25(3):201-11. PubMed ID: 25894564
[TBL] [Abstract][Full Text] [Related]
6. Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
Zheng X; Bair KW; Bauer P; Baumeister T; Bowman KK; Buckmelter AJ; Caligiuri M; Clodfelter KH; Feng Y; Han B; Ho YC; Kley N; Li H; Liang X; Liederer BM; Lin J; Ly J; O'Brien T; Oeh J; Oh A; Reynolds DJ; Sampath D; Sharma G; Skelton N; Smith CC; Tremayne J; Wang L; Wang W; Wang Z; Wu H; Wu J; Xiao Y; Yang G; Yuen PW; Zak M; Dragovich PS
Bioorg Med Chem Lett; 2013 Oct; 23(20):5488-97. PubMed ID: 24021463
[TBL] [Abstract][Full Text] [Related]
7. Discovery and characterization of novel small-molecule inhibitors targeting nicotinamide phosphoribosyltransferase.
Xu TY; Zhang SL; Dong GQ; Liu XZ; Wang X; Lv XQ; Qian QJ; Zhang RY; Sheng CQ; Miao CY
Sci Rep; 2015 Jun; 5():10043. PubMed ID: 26040985
[TBL] [Abstract][Full Text] [Related]
8. Nicotinamide phosphoribosyltransferase (Nampt) in carcinogenesis: new clinical opportunities.
Chen H; Wang S; Zhang H; Nice EC; Huang C
Expert Rev Anticancer Ther; 2016 Aug; 16(8):827-38. PubMed ID: 27186719
[TBL] [Abstract][Full Text] [Related]
9. Structural Basis of Beneficial Design for Effective Nicotinamide Phosphoribosyltransferase Inhibitors.
Tanuma SI; Katsuragi K; Oyama T; Yoshimori A; Shibasaki Y; Asawa Y; Yamazaki H; Makino K; Okazawa M; Ogino Y; Sakamoto Y; Nomura M; Sato A; Abe H; Nakamura H; Takahashi H; Tanuma N; Uchiumi F
Molecules; 2020 Aug; 25(16):. PubMed ID: 32785052
[TBL] [Abstract][Full Text] [Related]
10. Identification of novel Nicotinamide Phosphoribosyltransferase (NAMPT) inhibitors using computational approaches.
Kesherwani M; Raghavan S; Gunasekaran K; Velmurugan D
J Biomol Struct Dyn; 2018 Apr; 36(5):1306-1328. PubMed ID: 28514875
[TBL] [Abstract][Full Text] [Related]
11. Structural and biochemical analyses of the catalysis and potency impact of inhibitor phosphoribosylation by human nicotinamide phosphoribosyltransferase.
Oh A; Ho YC; Zak M; Liu Y; Chen X; Yuen PW; Zheng X; Liu Y; Dragovich PS; Wang W
Chembiochem; 2014 May; 15(8):1121-30. PubMed ID: 24797455
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Novel Inhibitors and Fluorescent Probe Targeting NAMPT.
Wang X; Xu TY; Liu XZ; Zhang SL; Wang P; Li ZY; Guan YF; Wang SN; Dong GQ; Zhuo S; Le YY; Sheng CQ; Miao CY
Sci Rep; 2015 Jul; 5():12657. PubMed ID: 26227784
[TBL] [Abstract][Full Text] [Related]
13. Inhibitor of Nicotinamide Phosphoribosyltransferase Sensitizes Glioblastoma Cells to Temozolomide via Activating ROS/JNK Signaling Pathway.
Feng J; Yan PF; Zhao HY; Zhang FC; Zhao WH; Feng M
Biomed Res Int; 2016; 2016():1450843. PubMed ID: 28097126
[TBL] [Abstract][Full Text] [Related]
14. Structure based design of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors from a phenotypic screen.
Palacios DS; Meredith E; Kawanami T; Adams C; Chen X; Darsigny V; Geno E; Palermo M; Baird D; Boynton G; Busby SA; George EL; Guy C; Hewett J; Tierney L; Thigale S; Weihofen W; Wang L; White N; Yin M; Argikar UA
Bioorg Med Chem Lett; 2018 Feb; 28(3):365-370. PubMed ID: 29275937
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer.
Sampath D; Zabka TS; Misner DL; O'Brien T; Dragovich PS
Pharmacol Ther; 2015 Jul; 151():16-31. PubMed ID: 25709099
[TBL] [Abstract][Full Text] [Related]
16. Fragment-based design of 3-aminopyridine-derived amides as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
Dragovich PS; Zhao G; Baumeister T; Bravo B; Giannetti AM; Ho YC; Hua R; Li G; Liang X; Ma X; O'Brien T; Oh A; Skelton NJ; Wang C; Wang W; Wang Y; Xiao Y; Yuen PW; Zak M; Zhao Q; Zheng X
Bioorg Med Chem Lett; 2014 Feb; 24(3):954-62. PubMed ID: 24433859
[TBL] [Abstract][Full Text] [Related]
17. Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors.
Dong G; Chen W; Wang X; Yang X; Xu T; Wang P; Zhang W; Rao Y; Miao C; Sheng C
J Med Chem; 2017 Oct; 60(19):7965-7983. PubMed ID: 28885834
[TBL] [Abstract][Full Text] [Related]
18. Identification of benzothiophene amides as potent inhibitors of human nicotinamide phosphoribosyltransferase.
Chen W; Dong G; He S; Xu T; Wang X; Liu N; Zhang W; Miao C; Sheng C
Bioorg Med Chem Lett; 2016 Feb; 26(3):765-768. PubMed ID: 26755394
[TBL] [Abstract][Full Text] [Related]
19. Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD
Guo J; Lam LT; Longenecker KL; Bui MH; Idler KB; Glaser KB; Wilsbacher JL; Tse C; Pappano WN; Huang TH
Biochem Biophys Res Commun; 2017 Sep; 491(3):681-686. PubMed ID: 28756225
[TBL] [Abstract][Full Text] [Related]
20. Targeted Delivery of Cytotoxic NAMPT Inhibitors Using Antibody-Drug Conjugates.
Neumann CS; Olivas KC; Anderson ME; Cochran JH; Jin S; Li F; Loftus LV; Meyer DW; Neale J; Nix JC; Pittman PG; Simmons JK; Ulrich ML; Waight AB; Wong A; Zaval MC; Zeng W; Lyon RP; Senter PD
Mol Cancer Ther; 2018 Dec; 17(12):2633-2642. PubMed ID: 30242091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
